Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 10/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183753 | 0.93 | HDAC4 (0.42) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL1625398 | 0.89 | TSHR (0.45) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL2442297 | 0.87 | ACHE (0.44) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL25583300 | 0.86 | NPC1 (0.41) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL1008679 | 0.85 | ESR1 (0.42) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL22667407 | 0.85 | KIF11 (0.44) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL1492878 | 0.85 | KCNN4 (0.43) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL603775 | 0.85 | JAK2 (0.40) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL1013437 | 0.85 | TSHR (0.50) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL13809335 | 0.85 | JAK2 (0.40) | JAK2ROCK2PRKCQPRKCDROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10173074-B2 | Cancer stem cell vaccination and treatment | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-01-08 | — | — | US | disclosed |
| US-20150265848-A1 | CANCER STEM CELL VACCINATION AND TREATMENT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-24 | — | — | US | disclosed |
| US-8246983-B2 | Encapsulated arsenic drugs | NORTHWESTERN UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120149828-A1 | WATERBORNE POLYISOCYANATE COMPOSITION THAT PROVIDES A LOW FRICTION COATING | WEBB, DAVID | 2012-06-14 | — | — | US | disclosed |
| US-20110092452-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PANCREATIC CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-21 | — | — | US | disclosed |
| US-7807647-B2 | Methods and compositions for cancer therapy | PRONAI THERAPEUTICS, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20090197202-A1 | PHOTOSENSITIVE PLANOGRAPHIC PRINTING PLATE MATERIAL | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090118377-A1 | APOGOSSYPOLONE AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080260720-A1 | Systems and Methods for Inhibiting Metastasis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-23 | — | — | US | disclosed |
| US-7432304-B2 | Small molecule antagonists of Bcl-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080176319-A1 | Methods and compositions for modulating apoptotic pathways | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2008-07-24 | — | — | US | disclosed |
| US-20080118437-A1 | Diagnosis and treatment O prostate cancer | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-05-22 | — | — | US | disclosed |
| US-20070243192-A1 | Growth hormone receptor antagonist cancer treatment | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070213285-A1 | Methods and compositions for cancer therapy | PRONAI THERAPEUTICS, SOUTHWEST MICHIGAN INNOVATION CENTER (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070065498-A1 | Encapsulated arsenic drugs | NORTHWESTERN UNIVERSITY (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118377-A1 | APOGOSSYPOLONE AND THE USES THEREOF | BCL2, BAD, BAX | JAK2 2632/4885ROCK2 1006/4885PRKCQ 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.